


THIP

Cat. No.:	HY-10232		
CAS No.:	64603-91-4		
Molecular Formula:	C ₆ H ₈ N ₂ O ₂		
Molecular Weight:	140.14		
Target:	GABA Receptor		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (356.79 mM; ultrasonic and adjust pH to 3 with HCl)
 H₂O : 23.33 mg/mL (166.48 mM; Need ultrasonic)

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	7.1357 mL	35.6786 mL	71.3572 mL
	5 mM	1.4271 mL	7.1357 mL	14.2714 mL
	10 mM	0.7136 mL	3.5679 mL	7.1357 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 50 mg/mL (356.79 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (17.84 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (17.84 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (14.84 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

THIP (Gaboxadol) is a selective extrasynaptic GABA_A receptors (eGABARs) agonist (with blood-brain barrier permeability), shows an EC₅₀ value of 13 μM for δ-GABAAR. THIP induces strong tense GABA_A-mediated currents in layer 2/3 neurons, but shows an effect on miniature IPSCs. THIP can be used in studies of sleep disorders^{[1][2][3]}.

IC₅₀ & Target	$\alpha 4\beta 3\delta$ GABAAR 13 μ M (EC ₅₀)																																														
In Vitro	<p>THIP (1 μM; 5 s) induces a robust tonic GABA-mediated current in layer 2/3 neurons^[1]. THIP (1 μM; 1 s) shows no effect miniature IPSCs in layer 2/3 neurons^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td colspan="3">Layer 2/3 neurons (from male postnatal day 13-19 C57BL/6 mice)</td> </tr> <tr> <td>Concentration:</td> <td colspan="3">1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td colspan="3">5 s</td> </tr> <tr> <td>Result:</td> <td colspan="3">Induced a tonic current of 43.2 pA.</td> </tr> </table> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td colspan="3">Layer 2/3 neurons (from male postnatal day 13-19 C57BL/6 mice)</td> </tr> <tr> <td>Concentration:</td> <td colspan="3">1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td colspan="3">1 s</td> </tr> <tr> <td>Result:</td> <td colspan="3">Resulted in only minor changes in the amplitude and frequency of mIPSCs.</td> </tr> </table>			Cell Line:	Layer 2/3 neurons (from male postnatal day 13-19 C57BL/6 mice)			Concentration:	1 μ M			Incubation Time:	5 s			Result:	Induced a tonic current of 43.2 pA.			Cell Line:	Layer 2/3 neurons (from male postnatal day 13-19 C57BL/6 mice)			Concentration:	1 μ M			Incubation Time:	1 s			Result:	Resulted in only minor changes in the amplitude and frequency of mIPSCs.														
Cell Line:	Layer 2/3 neurons (from male postnatal day 13-19 C57BL/6 mice)																																														
Concentration:	1 μ M																																														
Incubation Time:	5 s																																														
Result:	Induced a tonic current of 43.2 pA.																																														
Cell Line:	Layer 2/3 neurons (from male postnatal day 13-19 C57BL/6 mice)																																														
Concentration:	1 μ M																																														
Incubation Time:	1 s																																														
Result:	Resulted in only minor changes in the amplitude and frequency of mIPSCs.																																														
In Vivo	<p>THIP (Gaboxadol) (0.5, 5.0 mg/kg; p.o.; single) shows a good oral utilization, with F_a values of 110% and 83% for dosage of 0.5 and 5.0 mg/kg, respectively^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td colspan="3">Sprague-Dawley rats (255-276 g)^[2].</td> </tr> <tr> <td>Dosage:</td> <td colspan="3">2.5 mg/kg (for i.v.); 0.5 and 5.0 mg/kg (for p.o.).</td> </tr> <tr> <td>Administration:</td> <td colspan="3">Oral gavage; intravenous injection; single.</td> </tr> <tr> <td>Result:</td> <td colspan="3">Pharmacokinetic Parameters of THIP 4 in Sprague-Dawley rats^[2].</td> </tr> <tr> <td></td> <td>IV (2.5 mg/kg)</td> <td>PO (0.5 mg/kg)</td> <td>PO (5.0 mg/kg)</td> </tr> <tr> <td>AUC (ng/mL·h)</td> <td>1193</td> <td>263</td> <td>1988</td> </tr> <tr> <td>T_{max} (h)</td> <td>-</td> <td>0.22</td> <td>0.33</td> </tr> <tr> <td>C_{max} (ng/mL)</td> <td>4350</td> <td>291</td> <td>2061</td> </tr> <tr> <td>CL/F_a (mL/h/kg)</td> <td>-</td> <td>1939</td> <td>2558</td> </tr> <tr> <td>CL (mL/h/kg)</td> <td>2043</td> <td>-</td> <td>-</td> </tr> <tr> <td>F_a (%)</td> <td>100</td> <td>110</td> <td>83</td> </tr> </table>			Animal Model:	Sprague-Dawley rats (255-276 g) ^[2] .			Dosage:	2.5 mg/kg (for i.v.); 0.5 and 5.0 mg/kg (for p.o.).			Administration:	Oral gavage; intravenous injection; single.			Result:	Pharmacokinetic Parameters of THIP 4 in Sprague-Dawley rats ^[2] .				IV (2.5 mg/kg)	PO (0.5 mg/kg)	PO (5.0 mg/kg)	AUC (ng/mL·h)	1193	263	1988	T _{max} (h)	-	0.22	0.33	C _{max} (ng/mL)	4350	291	2061	CL/F _a (mL/h/kg)	-	1939	2558	CL (mL/h/kg)	2043	-	-	F _a (%)	100	110	83
Animal Model:	Sprague-Dawley rats (255-276 g) ^[2] .																																														
Dosage:	2.5 mg/kg (for i.v.); 0.5 and 5.0 mg/kg (for p.o.).																																														
Administration:	Oral gavage; intravenous injection; single.																																														
Result:	Pharmacokinetic Parameters of THIP 4 in Sprague-Dawley rats ^[2] .																																														
	IV (2.5 mg/kg)	PO (0.5 mg/kg)	PO (5.0 mg/kg)																																												
AUC (ng/mL·h)	1193	263	1988																																												
T _{max} (h)	-	0.22	0.33																																												
C _{max} (ng/mL)	4350	291	2061																																												
CL/F _a (mL/h/kg)	-	1939	2558																																												
CL (mL/h/kg)	2043	-	-																																												
F _a (%)	100	110	83																																												

CUSTOMER VALIDATION

- Can J Physiol Pharmacol. 2020 Oct;98(10):725-732.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Drasbek KR, et al. THIP, a hypnotic and antinociceptive drug, enhances an extrasynaptic GABAA receptor-mediated conductance in mouse neocortex. Cereb Cortex. 2006 Aug;16(8):1134-41.
- [2]. Larsen M, et al. 5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination. Eur J Pharm Sci. 2010 Jan 31;39(1-3):68-75.
- [3]. Hoestgaard-Jensen K, et al. Probing $\alpha 4\beta\delta$ GABAA receptor heterogeneity: differential regional effects of a functionally selective $\alpha 4\beta 1\delta/\alpha 4\beta 3\delta$ receptor agonist on tonic and phasic inhibition in rat brain. J Neurosci. 2014 Dec 3;34(49):16256-72.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA